ArticleInternational journal of chronic obstructive pulmonary disease2026
Exacerbations and Healthcare Burden of COPD with Type 2 Inflammation: US Claims Analysis.
Article in International journal of chronic obstructive pulmonary disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Up to 40% of patients with chronic obstructive pulmonary disease (COPD) have type 2 inflammation, characterized by an elevated blood eosinophil count (BEC), with limited real-world evidence of disease burden. Methods: Retrospective analysis using Optum's Clinformatics Results: There were 13,840 eligible patients (6,389 EXAC-EP-150; 3,100 EXAC-EP-300; 7,451 reference). During 12-month follow-up, the mean (95% confidence interval) rates of any COPD-related exacerbations were similar in the EXAC-EP-150 and EXAC-EP-300 groups, both higher versus the reference group (1.58 [1.53, 1.63] and 1.56 [1.50, 1.63] vs 0.52 [0.50, 0.54]). Similarly, COPD-related HCRU and medical costs were higher in the EXAC-EP-150/300 groups than the reference group. Conclusion: Patients with COPD and type 2 inflammation experiencing exacerbations despite triple therapy have high exacerbation rates, HCRU, and medical costs, highlighting the need for improved management of this patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.